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Abstract
OBJECTIVES: We have previously demonstrated the functionality and growth of autologous, living, tissue-engineered vascular grafts
(TEVGs) in long-term animal studies. These grafts showed substantial in vivo tissue remodeling and approximation to native arterial wall
characteristics. Based on this, in vitro and in vivo matrix metalloproteinase (MMP) activity of TEVGs is investigated as a key marker of
matrix remodeling.
METHODS: TEVGs fabricated from biodegradable scaffolds (polyglycolic-acid/poly-4-hydroxybutyrate, PGA/P4HB) seeded with autolo-
gous vascular cells were cultured in static and dynamic in vitro conditions. Thereafter, TEVGs were implanted as pulmonary artery repla-
cements in lambs and followed up for 2 years. Gelatin gel zymography to detect MMP-2 and -9 was performed and collagen content
quantiﬁed (n = 5). Latent (pro) and active MMP-2 and -9 were detected.
RESULTS: Comparable levels of active MMP-9 and pro-MMP-2 were detected in static and dynamic culture. Higher levels of active
MMP-2 were detected in dynamic cultures. Expression of MMP-2 and -9 was minimal in native grafts but was increased in implanted
TEVG. Pro-MMP-9 was expressed 20 weeks post implantation and persisted up to 80 weeks post implantation. Collagen content in vitro
was increased in dynamically conditioned TEVG as compared with static constructs and was increased in vivo compared with the corre-
sponding native pulmonary artery.
CONCLUSIONS: MMPs are up-regulated in vitro by dynamic culture conditions and could contribute to increased matrix remodeling,
native analogous tissue formation and functional growth of TEVGs in vivo. Monitoring of MMP activity, for example, by molecular
imaging techniques, may enable the non-invasive assessment of functional tissue quality in future clinical tissue-engineering
applications.
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INTRODUCTION
Tissue-engineering technologies continue to address the critical
need for living autologous tissue substitutes with growth poten-
tial in congenital cardiac surgery. Applications of biological and
engineering principles strive to construct tissues with characteris-
tics of healthy native tissues from their cellular components. For
reconstruction of the right-ventricular outﬂow tract, the use of
homografts, xenografts, and polytetraﬂuoroethylene (PTFE) grafts
remains the mainstay of surgical treatment options, despite vari-
able results and degrees of success. The need, however, for sur-
gical re-interventions is inevitable in many situations due to
conduit failure as well as the inability of these conduits to grow
with the child.
The feasibility of creating implantable large- and small-caliber
tissue-engineered vessels for systemic and low-pressure
applications has been demonstrated experimentally and in initial
clinical trials. Functional arteries have been grown in vitro both
using animal and human cells [1–3]. Recently, we have demon-
strated that tissue-engineered vascular grafts (TEVGs) implanted
as autologous, living, pulmonary artery replacements showed ex-
cellent functionality and growth in long-term large animal
follow-up studies covering the full biological growth cycle of the
animal model [4]. Interestingly, these growing and functional
tissue-engineered arteries demonstrated substantial remodeling
over time, and, most importantly, structural approximation to
native arterial wall tissue composition. The normal arterial wall
consists of an intimal layer, a media layer, and an adventitial
layer. Vascular remodeling and structural adaptation of
tissue-engineered grafts in response to hemodynamic stresses
based on constant cellular activity appear to be a prerequisite
for growth and sustained functionality [4].
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Vascular smooth muscle cells (VSMCs) are the main cellular
components of the arterial wall and provide vascular tone and
the arterial wall extracellular matrix. Facilitating SMC growth, mi-
gration, basement-membrane breakdown, angiogenesis, and
other aspects of vascular remodeling necessitates an ongoing
degradation and reorganization of extracellular matrix. First
described in 1962 by Gross and Lapiere [5], 26 described matrix
metalloproteinases (MMPs) contribute to extracellular matrix re-
modeling. MMPs are zinc-dependent peptidases broadly classi-
ﬁed according to their substrate-degradation properties. They
are synthesized in the latent form as zymogens and secreted as
pro-enzymes (pro-MMPs). Activation occurs via a process
known as the cysteine-Zn+ switch [6], which enables proteolytic
activity. In this study, we identiﬁed MMPs as important enzymes
in TEVG remodeling. The functions of MMPs are not fully under-
stood; however, they are of interest in physiological processes,
such as pregnancy [7], and have also been reported to be asso-
ciated with pathologic phenomena [8–10]. In vascular tissue en-
gineering, MMP-related processes are expected to be of critical
importance for tissue homeostasis and functional growth. With
the aim of a more meticulous understanding of long-term re-
modeling mechanisms, tissue-engineered autologous living pul-
monary arteries were analyzed for MMP-2 and -9 expression as
well as collagen content and compared with native arterial
tissue. SMCs produce pro-MMP-2 in normal arterial wall and in
culture, but active MMP-2 and pro- and active MMP-9 are
absent [11–13]. By contrast, injured and diseased vessels under-
going remodeling produce active MMP-2 and MMP-9 [11,12,14].
Consequently, in this study, we focused on the expression of the
gelatinases MMP-2 and-9. MMP-2 has been shown to degrade
native type IV, V, VI, and X collagen as well as denatured colla-
gen, proteoglycans, elastin, and growth factors [15]. MMP-9
degrades gelatin, an irreversibly hydrolyzed collagen, and is
expressed following injury or inﬂammatory stimulation [16]. In
the light of these observations and the so-far limited under-
standing with regard to tissue engineering [17], the long-term
MMP expression in autologous, living TEVGs implanted as pul-
monary artery replacements in a growing large animal model is
investigated.
MATERIAL AND METHODS
The general approach to cell isolation, culture, and seeding has
been described in detail [4,18]. All investigations performed in
this work are based on tissue samples generated in a previous
study focusing on functional performance of tissue-engineered
arteries in a growing long-term animal model [4]. All procedures
were conducted according to Swiss regulations on animal
welfare and permission granted by the ethical committee
(Permission Nr. 71/2002, 91/2004).
In vitro production of TEVGs
Bioabsorbable pulmonary artery scaffolds were fabricated from
non-woven polyglycolic-acid mesh (PGA, thickness 1.0 mm, spe-
ciﬁc gravity 70–90 mg cm−3, Cellon SA, Luxembourg) coated
with poly-4-hydroxybutyrate (P4HB, molecular weight 1 × 106,
PHA 4400, Tepha Inc., Lexington, MA, USA). Based on biopsies
of peripheral blood vessel (Swiss White Alpine lambs), endothe-
lial cells were obtained using a collagenase-instillation technique.
Following isolation, they were cultured in tissue culture ﬂasks
(Nunc™, Roskilde, Denmark) with endothelial basal medium
(EBM-2) medium supplemented with 10% lamb serum (GIBCO,
NY, USA). To obtain myoﬁbroblasts, the remaining
de-endothelialized vessel segments were minced and cultured in
Dulbecco’s modiﬁed Eagle Medium (DMEM) or advanced
DMEM (GIBCO, NY, USA) supplemented with 10% lamb serum,
2 mM glutaMAX (GIBCO, NY, USA) and 50 μg ml−1 gentamycin
(GIBCO, NY, USA). After myoﬁbroblast migration onto the dishes
(after 5–7 days), the cells were serially passaged and expanded in
a humidiﬁed incubator at 37 °C and 5% CO2. Sufﬁcient cell
numbers for cell seeding were obtained in pure culture after
10–14 days.
Myoﬁbroblasts (4.5–5.5 × 106 cm−2) were sequentially seeded
onto the vascular scaffolds, followed by endothelial cell seeding
(1 × 106 cm−2) phenotypically conﬁrmed by von Willebrand
Factor (vWF) presence. Thereafter, the constructs were trans-
ferred into a pulse duplicator system [18] and grown under
gradually increasing nutrient medium ﬂow conditions
(50–550 ml min−1, 1 Hz) for 14 days. Control TEVGs were grown
accordingly, but in static nutrient. Media were changed every
3–4 days.
In vivo implantation of TEVGs
The TEVGs were surgically implanted as replacements of the
main pulmonary artery into lambs, as described in detail as pre-
viously described in Circulation 2006 [4].
Computed tomography (CT)–angiography analysis
Computed tomography (CT)–angiography scans were performed
under general anesthesia on a 64-slice scanner with a 0.37-s
rotation time (Somatom Sensation 64™, Siemens, Forchheim,
Germany). A bolus of Iodixanol (270 mg ml−1, Amersham Health,
UK) was injected into a forearm vein at a ﬂow rate of 4 ml s−1,
using 2 ml of contrast agent per kg. Slices with a thickness of
0.75 mm (increment 0.5 mm) and a medium soft-tissue recon-
struction kernel (B30f ) were used for evaluation.
Analyses of TEVG explants
Out of a total of 14 animals [4], a subgroup of ﬁve TEVGs
samples was investigated as to MMP proﬁles, microstructure,
and tissue composition. A representative longitudinal sample of
each TEVG was ﬁxed in 10% phosphate-buffered formalin (pH
7.0) and embedded in parafﬁn. Each cross section included
native tissue proximal as well as distal to the entire length of the
TE construct. Routine histological staining was by hematoxylin
and eosin (H&E) and Masson’s trichrome. Immunohistochemical
stainings were performed using the Ventana Benchmark auto-
mated staining system (Ventana Medical Systems, Tucson, AZ,
USA) with Ventana reagents for the entire process. Primary anti-
bodies against the following antigens were applied: vWF(poly-
clonal rabbit anti-vWF antibodies; all from DakoCytomation,
Glostrup, Denmark), alpha smooth muscle actin (monoclonal
mouse anti-αSMA, clone 1A4; Sigma), and desmin (monoclonal
mouse anti-desmin, clone D33). Primary antibodies were
detected with the Ventana iVIEW DAB detection kit, resulting in
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a brown reaction product. Counterstaining was performed with
hematoxylin. As an indicator for collagen formation, the hydro-
xyproline content of lyophilized samples was determined, as
described by Huszar et al. [19].
MMP-2 and -9 were detected by gelatin zymography, as pre-
viously described [14]. Brieﬂy, sodium dodecylsulfate (SDS) cell
lysates were subjected to electrophoresis on 7.5% (w/v) polya-
cryalamide gel electrophoresis (PAGE) gel containing 0.2% (w/v)
SDS supplemented with 2 mg ml−1 gelatin. All gels were cali-
brated with a high-molecular-mass protein standard mixture. In
addition, for standardization, on each gel, an aliquot of a stand-
ard conditioned medium collected from HT1080 cells (which
secrete both MMP-2 and -9) was run.
Statistical analysis
Analysis of variance was performed to estimate the means and
the signiﬁcance of the categorical factors using Statistical
Package for Social Sciences (SPSS) version 16 (SPSS, Inc.,
Chicago, IL, USA). A paired t-test was performed comparing
native tissue to tissue-engineered samples. A p-value <0.05 was
considered as signiﬁcant.
RESULTS
Static and dynamically cultured TEVGs were analyzed and com-
pared with tissue engineered and native in vivo samples at 20
(TE20, n = 1), 50 (TE50, n = 2), and 80 (TE80, n = 2) weeks post
implantation. A macroscopic image of the tissue-engineered
graft at time of implantation is shown in Fig. 1. Masson’s tri-
chrome staining of a pre-implant conduit showed collagen
within the extracellular matrix, as blue color. H&E staining
showed layered tissue formation of the pre-implant conduit
(Fig. 2(a) and (b)). As early as 20 weeks post implantation, the
macroscopic external appearance of the pulmonary conduit was
indistinguishable from native tissue (Fig. 3).
Morphology
At the time of sacriﬁce, the tissue-engineered pulmonary artery
graft was dissected out in toto. The TEVGs were carefully
Figure 1: Tissue engineered vascular graft (TEVG) after of surgical implant-
ation as main pulmonary artery replacement.
Figure 2: (a) Trichrome Masson (TM) staining of pre-implant TEVG showing collagen staining in blue. (b) Hematoxylin and Eosin (H&E) staining of pre-implant
TEVG showing layered tissue formation within the pre-implant TEVG (the bar represents 200 μm).
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observed for signs of thrombus formation, calciﬁcation and
obvious stenosis, or aneurysmal formation. There were no signs
of morphological abnormalities in any of the animals included.
The luminal layer appeared smooth and continuous with the
native pulmonary artery and free of calciﬁcation or thrombus
formation.
Tissue microstructure and composition
The triple-layered tissue-engineered pulmonary artery consisted
of an intima, a media, and an adventitial layer reminiscent of
native artery. At TE20, TE50, and TE80, there is an increasing vas-
cular SMC distribution within the TEVGs, with a corresponding
increased collagen deposition in the extracellular matrix with
time (Fig. 4).
Collagen content in vitro and in vivo, as measured by hydroxy-
proline content, increased signiﬁcantly in dynamically condi-
tioned constructs as compared with static constructs (Fig. 5(a))
with the dynamically generated TEVGs having a hydroxyproline
content of 4.08 ± 1.9 μg mg−1 dry weight. The hydroxyproline
content was signiﬁcantly increased in tissue-engineered
constructs compared with native pulmonary artery (Fig. 5(b)).
Native pulmonary artery collagen content was
18.8 ± 3.6 μg mg−1 dry weight. At 20 weeks post implantation
(TE20), the tissue-engineered conduit had a collagen content of
29.03 ± 4.14 μg mg−1 dry weight. As seen in Fig. 5(b), the colla-
gen content increases up to 42.3 ± 2.98 μg mg−1 dry weight at
TE80.
MMP activity
MMP expression was detected as clear bands on the blue back-
ground of the stained gel, due to lysis of the gelatin. These
bands correspond to the predicted molecular weights of MMP-2
and -9 and correspond with the positive control. MMP-2 and
MMP-9 exist in both latent and active forms, with molecular
weight of latent MMP-2 being 72 kDa and that of latent MMP-9
being 92 kDa. Comparable levels of active MMP-9 and
pro-MMP-2 were detected in VSMCs in static and dynamic
culture. However, higher levels of active MMP-2 were detected
in TEVGs in dynamic cultures as compared with static culture
(Fig. 6). Expression of MMP-2 and MMP-9 was minimal in native
grafts but was increased in implanted tissue-engineered grafts
(Fig. 7). Both latent and pro-MMP-2 and -9 expression was
observed as early as TE20 and persists up to TE80 (Fig. 7).
DISCUSSION
More than 20 years ago, Weinberg and Bell produced a collagen-
based vascular conduit by isolating aortic bovine endothelial,
Figure 4: Trichrome Masson (TM) staining of explanted TEVG at 20 weeks
post implantation showing collagen staining in blue (The bar represents
200 μm).
Figure 3: Macroscopic image of an explanted TEVG at 20 weeks post implant-
ation. There is no evidence of thrombus or calciﬁcation and the TEVG shows
a smooth luminal surface.
Figure 5: (a) Collagen content of static versus dynamic pre implant grafts.
There is a signiﬁcant difference between dynamic versus static samples
(p = 0.05) (b). Collagen content of 5 TEVG at 20 (TE20), 50 (TE50) and 80
(TE80) weeks post implantation versus native (N) pulmonary artery. There is a
signiﬁcant difference between native and TE 50 (p < 0.05) and TE 80
(p < 0.05) samples.
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smooth muscle, and adventitial ﬁbroblast cells [20]. Although not
implanted in vivo, these constructs showed sufﬁcient burst
strength and structural features of arterial tissue. Since these
early days, tissue engineering has combined principles of cell
biology with biomechanical engineering, leading to advances in
the ﬁeld [21].
Various cell sources have been investigated for cardiovascular
applications both in animal and in human models [1]. Shin’oka
et al. used bone-marrow-derived cells intra-operatively seeded
onto vascular scaffolds as pulmonary artery replacements in pediat-
ric patients with adequate functionality [3]. The histological results
elucidating the growth potential of these grafts are awaited. Others
have used human ﬁbroblast cells in scaffold-free tissue-engineering
applications for small-diameter blood vessels [22].
However, little is known regarding the post-implantation
tissue-remodeling processes observed to a substantial degree in
most experimental studies. It appears that, apart from the initially
seeded cells, endogenous cell re-population phenomena con-
tribute importantly to these remodeling processes comprising
somatic growth and long-term functionality. With regard to
future routine clinical use of the tissue-engineering technology,
a meticulous understanding of the underlying remodeling
mechanisms will be of crucial importance. Furthermore, safety
parameters assessable in a non-invasive fashion after implant-
ation may be a prerequisite for the safe translation of clinical
tissue engineering into clinical practice. It is anticipated that such
assessments may be performed by molecular-imaging method-
ologies, such as magnetic resonance imaging, which can monitor
enzymatic activities of MMPs [23].
Ideal tissue-engineered conduits should show durability,
absence of thrombus formation, resistance to infections, lack of
immunological complications, and, most importantly, potential
for growth. We have shown functional growth and approxima-
tion of tissue-engineered pulmonary arteries to native tissue in
animal studies. Long-term follow-up of animals with autologous
ovine cells seeded onto a biodegradable scaffold and implanted
in the pulmonary position has conﬁrmed both feasibility and
functional growth of the tissue-engineered conduits based on CT
and echocardiography data [4].
Improvements in bioreactor technology and physiological pre-
conditioning in vitro have been shown to stimulate extracellular
matrix formation in vitro. Collagen formation was signiﬁcantly
increased in the dynamic pre-implantation TEVG as compared
with static culture. In our lamb model, as early as 20 weeks post-
operatively, collagen formation in the tissue-engineered graft
had already exceeded native pulmonary artery, with continued
deposition leveling in at TE80.
The long-term role of MMPs in pulmonary artery tissue engin-
eering in a growing animal model has been unknown so far.
MMPs play a signiﬁcant role in tissue remodeling and have been
extensively investigated in pregnancy [7], as well as in pathological
processes, such as hypertension [8], atherosclerosis [10], and
aneurysmal formation [9]. All of these processes show degrad-
ation of extracellular matrix and remodeling by MMP activity.
To date, there is only limited knowledge as to the role of
MMPs in the remodeling of tissue-engineered cardiovascular
structures [17], particularly with regard to MMP activity during
somatic growth. Our results have conﬁrmed MMP-2 and MMP-9
as key enzymes in tissue-engineered vascular remodeling with
ongoing MMP-2 and MMP-9 activity up to TE80 weeks. In vitro,
there was an up-regulation of active MMP-2 as a result of bio-
mimetic, dynamic culture conditions. Once implanted, there
appears to be constant recruitment of cells into the implanted
tissue-engineered graft to maintain tissue homeostasis and sus-
tained functionality [4]. The origin of these cells is under investi-
gation and may include blood-born stem cells as well as cells
from the peri-vascular environment [24]. Histologically, the
media layer of the tissue-engineered graft showed ﬁbroblasts
and collagen deposition with a rich capillary network. This, to-
gether with the hemodynamic stresses of the pulmonary circula-
tion, would account in part for the increased activated MMP-2
and MMP-9 activity in the tissue-engineered graft. The enzymat-
ic activity is ongoing throughout the TE80 period, even though
there is complete degradation of the biodegradable polymer
and therefore absence of foreign body phenomena in the graft.
The MMP-2 activity in native tissue does not appear to vary sig-
niﬁcantly at the various time points, despite being subjected to
the same hemodynamic stresses as the TEVGs. This implies that
hemodynamic stresses alone do not account for the increased
MMP activity in vivo, which rather reﬂects the adaptive tissue re-
modeling activities resulting in the observed functionality and
growth of the TEVGs. Therefore, MMP activity could be regarded
and used as an indicator of ‘guided healing processes’. MMP-9
activity is markedly up-regulated in the tissue-engineered grafts
in conjunction with a signiﬁcantly increased collagen production
as compared with native tissue. Histologically, a corresponding
increase in VSMCs in tissue-engineered implants is observed
with time.
Indeed, MMPs have been demonstrated to be linked with
aneurysms and atherosclerotic processes [8–10]. However, both
echocardiography and CT data did not display any aneurysmal
formation or atherosclerotic signs as also conﬁrmed by detailed
histology [4]. To the contrary, functional growth with arterial wall
structures approximating native arterial layers over time were
observed. Thus, the increased MMP activity in TEVGs appears
not to be attributed to these pathological processes, but the
result of increased cellular recruitment, which use MMP-2 and
-9 to migrate or invade the tissue-engineered graft similarly seen
Figure 7: MMP-2 and -9 expression in TEVG (TE) versus native (N) at 20, 50
and 80 weeks after implantation. The TE pulmonary artery (TE), site of anasto-
mosis (TE/N) between TE and native as well as native (N) PA were subjected
to gelatin zymography. Both active and pro(latent) MMPs are indicated.
Figure 6: MMP-2 and -9 expression in vascular smooth muscle controls,
dynamic (n = 2) and static (n = 2) culture conditions. Gelatinolytic zymogra-
phy was performed to detect MMP-2 and MMP-9. Active and pro(latent)
forms are indicated.
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in classical healing processes. In addition, there was no evidence
of calciﬁcation, thrombus formation, or stenosis within the
tissue-engineered graft, further suggesting the absence of patho-
logical processes.
Our observations raise questions in terms of the differences
which exist between tissue-engineered and native vascular grafts.
The presence of increased MMP activity even in the long-term
grafts suggests a sustained remodeling activity to maintain tissue
homeostasis and functionality. Further studies will be necessary to
evaluate the role of other classes of MMPs and the effects of inhi-
biting MMP activity with regard to functionality, long-term growth
potential, and performance of tissue-engineered vascular grafts.
Based on a more detailed understanding of matrix remodeling,
modern magnetic resonance and molecular imaging techniques
may allow for non-invasive tracking of MMP activity in clinical set-
tings [25]. Such methodologies enabling the deﬁnition of clinically
relevant quality criteria may contribute to the safe translation of
tissue-engineering technologies to routine clinical practice. In add-
ition, this growing insight into the remodeling mechanisms involv-
ing MMPs could help to speciﬁcally design intelligent scaffold
materials. These may support remodeling phenomena within
tissue-engineered constructs in the future by attaching transcrip-
tion factors and/or cytokines to the starter matrices.
Conﬂict of interest: none declared.
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